THC Global Group Executive Personnel And Management Ken Charteris Group Chief Executive Officer Ken is a veteran of multiple biotech and pharmaceutical companies over the past three decades as CEO, Managing Director and Chairman. In previous Executive roles Ken has had full P&L and balance sheet responsibility including legal and financial compliance in listed and international structures, leading businesses with revenue exceeding $200m and asset bases within $100m - $500m. Ken has a proven track record in hands on roles within major listed international companies improving profit growth and effecting share price increase. Ken was involved in various senior levels within THC since prior to listing on the ASX, Ken has been instrumental in the execution of the Company’s strategic plan, including the acquisition of THC’s manufacturing facility and the securing of commercial partnerships with Ascent Industries (North America) and Endoca (Europe). Ken has a specific mandate to drive future acquisitions and alliances for THC. Mark FortugnoChief Financial Officer Mark has over 15+ years growing businesses internationally across Australia, Canada, the USA, Asia Pacific from start-up, to SME, corporates and multinationals. Mark’s strategic and leadership experience spans finance, general management, operations, facilities management, business development, investment consulting, human capital, and restructuring. Mark has completed Leadership and Negotiations programs at the Harvard Club of Australia, in addition to governance training at the Australian Institute of Company Directors. Mark holds a Post- Graduate Degree in Accountancy and a Bachelor of Commerce with Distinction. Mark’s strategic growth knowhow was forged across iconic groups including KPMG, SNC-Lavalin, and Cater Care Group. His specialist expertise includes strategy, investment and commercial appraisals, capital management and treasury, financial planning and analysis across international markets. Dr Michael HarrisonAPI Manager - Pharmaceutical Botanicals Manufacturing Michael has a doctorate in chemical engineering with over 20 years’ experience in bio-extraction of APIs. Michael was a production manager at Leo Pharma before joining THC Pharma, with a sound knowledge of the manufacturing bio-extract facility, GMP and API processes. Michael will lead new process and formula development at the R&D and manufacturing facility. John HallCannabis Strain Development & Agronomy John Hall brings over 30 years’ experience in plant breeding, crop management and monitoring systems, as well as directorships of several companies. He has worked extensively in crop nutrition, including hydroponics, and was involved in breeding 7 of 9 registered industrial hemp varieties in Australia for the company. John has also consulted extensively in Australia, USA, Europe and Asia. He developed a unique system for remote crop monitoring and integrated management which has been adopted in six countries. Dr Andrew Beehag Lead, Medicinal Cannabis Division Andrew led the establishment of this business at its inception in 2016 including its successful licensing and partnership alliancing with Endoca and BOL Pharma and will continue to build THC’s successful investment and partnership strategy gearing up THC to supply to domestic patients and the export market in the near to medium term. Andrew’s key skills include creation and execution of strategic plans, operations and personnel management, intellectual property management and commercialisation, budgeting and financial forecasting, stakeholder negotiation and management, project management, public speaking and development of high performing teams. Katy Williams Day Pharmaceutical Product & Regulatory Affairs Manager Katy is qualified as a Master of Pharmacy with more than 20 years of experience in the regulatory, market, quality and clinical development of pharmaceutical products. Her career includes roles as Head of Medical Affairs, Head of Regulatory & Scientific Affairs, Director of Regulatory Affairs and Quality with organisations including Merck Serono, Phebra, Sandoz, Pfizer and Genzyme. Katy is also experienced in patient advocacy approaches critical to successful medicinal cannabis product adoption. Brett SvedinekLaboratory Supervisor - Pharmaceuticals Botanical Manufacturing Brett is qualified with a Bachelor of Science with majors in Chemistry & Environmental Science, with more than 10 years experience in pharmaceutical testing laboratories. Brett’s career includes roles as laboratory analyst, senior analyst and laboratory specialist with multi-national company Leo-pharma in an TGA & FDA audited and accredited laboratory. During his career Brett has overseen several laboratory upgrade projects to allow for the testing of new product lines and increased throughput.